drugset / Trial / NCT05995444

A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects

NCT05995444

Phase 1 Completed 24 enrolled AN2 Therapeutics, Inc
RandomizedCrossoverQuadruple-blindBasic science

Summary

A single-center, 4-way crossover study to evaluate the effect of single therapeutic and supratherapeutic oral doses of epetraborole on the heart rate (HR) corrected QT interval (QTc) by assessing concentration-QT (C-QT) relationship using exposure-response modeling.

Timeline

Start
2023-06-05
Primary completion
2023-07-26
Completion
2023-08-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Epetraborole Small molecule 500 mg Oral
Subject Epetraborole Small molecule 2000 mg Oral
Comparator Moxifloxacin Small molecule 400 mg

Indications

No indication recorded.